The role of receptor for advanced glycation end products in airway inflammation in CF and CF related diabetes

Siobhain Mulrennan, Svetlana Baltic, Shashi Aggarwal, J. Wood, A. Miranda, F.A. Frost, J. Kaye, Philip Thompson

    Research output: Contribution to journalArticle

    25 Citations (Scopus)

    Abstract

    Cystic Fibrosis (CF) is often accompanied by diabetes leading to worsening lung function, the reason for which is unclear. The receptor for advanced-glycation-end-products (RAGE) regulates immune responses and inflammation and has been linked to diabetes and possibly CF. We performed a pilot study to determine if CF and CF-related diabetes (CFRD) are associated with enhanced RAGE expression. Full length (fl)RAGE, soluble (s)RAGE, endogenous soluble (es)RAGE, S100A12 (enRAGE) and advanced-glycation-end-products (AGE) expression was assessed in serum, white blood cells and sputum of patients with CF; diabetes; CFRD and healthy subjects. Sputum enRAGE/sRAGE ratios were high in CF but particularly in CFRD which negatively correlated with % predicted FEV1. Serum AGE and AGE/sRAGE ratios were high in diabetics but not in CF. A complex, multifaceted approach was used to assess the role of RAGE and its ligands which is fundamental to determining their impact on airway inflammation. There is a clear association between RAGE activity in the airways of CF and CFRD patients that is not evident in the vascular compartment and correlates with lung function, in contrast to diabetes. This strongly suggests a role for RAGE in contributing to the inflammatory overdrive seen in CF and to a greater extent in CFRD.
    Original languageEnglish
    Pages (from-to)8931
    JournalScientific Reports
    Volume5
    DOIs
    Publication statusPublished - 2015

    Fingerprint Dive into the research topics of 'The role of receptor for advanced glycation end products in airway inflammation in CF and CF related diabetes'. Together they form a unique fingerprint.

    Cite this